Project Grant R01DK142211

Award Date 9/20/24
Completion Date 7/31/29
Dollars Obligated $599K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,018,167 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to study the mechanisms behind benign prostatic hyperplasia (BPH) and non-responsiveness to steroid 5a-reductase inhibitor (5ARI) therapy. The research aims to elucidate how decreased expression of the SRD5A2 enzyme and...
This $1,350,373 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to elucidate the role of lipid accumulation and foam cells in benign prostate disease. The project, conducted by Old Dominion University and its research foundation, aims to: 1) investigate the impact of the cytokine CXCL17 on the prostatic immune environment in mice...
This Project Grant award, valued at $629,250.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research to examine the role of hyaluronic acid (HA) in the pathobiology of benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS). The primary objectives are to characterize the relationship between HA,...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,428,186.00 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on the role of CYP4F enzymes in regulating N-acyl amino acid signaling in humans. The project aims to biochemically characterize N-acyl amino acids as substrates and inhibitors of CYP4F...
This federal Project Grant award of $675,660.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award was granted to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research focused on understanding the regulation and requirements for coenzyme A (CoA) biosynthesis, and how dysregulation of CoA synthesis is related to metabolic diseases...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $133,500 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Boston Medical Center Corporation (BMC) with a start date of September 1, 2024 and end date of August 31, 2026. The grant will fund research on the relationship between APOL1 genotypes and biomarkers of immune activation and tubular injury in the context of chronic kidney disease (CKD) in sub-Saharan...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,145,486 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Makscientific LLC, a for-profit research and development company located in Burlington, MA. The grant supports the development of novel peripherally acting CB1 neutral antagonists for treating diabetic kidney disease (DKD). The project aims to design and synthesize improved analogs of...
The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $243,750 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Trustees of the University of Pennsylvania. The grant will fund the development of novel methods to improve detection of mosaic chromosomal alterations (MCA) in non-neoplastic tissues like the kidney and blood. The project aims to create single-cell sequencing techniques and spatial...
The National Institute on Aging (NIA) awarded a $489,509 Project Grant (CFDA 93.866 - Aging Research) to the Magee-Womens Research Institute And Foundation to conduct research on steroid hormone pathways regulating benign prostate hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with aging. The 2-year project aims to: Identify proteins and pathways involved in promoting smooth muscle relaxation and bladder voiding that are dysregulated in aged mouse prostate models and...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $598,609 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA. The grant, running from September 20, 2024 to July 31, 2029, aims to clinically evaluate mechanisms of resistance to the 5α-reductase inhibitor finasteride, a common drug used to manage benign prostatic hyperplasia (BPH) and lower urinary tract symptoms. The research will assess whether methylation status of the SRD5A2 gene, which regulates prostate growth, can predict response to 5α-reductase inhibitor therapy, and evaluate whether inflammatory markers can serve as non-invasive predictors of SRD5A2 methylation. The project will also explore the potential for combination therapy using 5α-reductase inhibitors and selective estrogen receptor modulators as an alternative treatment strategy for men demonstrating resistance to 5α-reductase inhibitor monotherapy.

Generated 7/1/25, 3:33 AM